Long-term results of a phase II trial of induction paclitaxel-carboplatin followed by concurrent radiation therapy and weekly paclitaxel and consolidation paclitaxel-carboplatin in stage III non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 1, 2011, Pages 79-85

  Casas, Francesc ^a   Viñolas, Núria ^a   Ferrer, Ferran ^b   Agustí, Carles ^c   Sanchez, Marcelo ^c   Maria Gimferrer, Josep ^c   Lomeña, Francisco ^d   Campayo, Marc ^a   Jeremic, Branislav ^b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b Radiation Oncology Department   (Spain)

^c Hospital Clinic   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DYSPNEA; ESOPHAGUS DYSFUNCTION; ESOPHAGUS STENOSIS; ESOPHAGUS TOXICITY; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; LONG TERM CARE; LUNG INFILTRATE; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PLAQUETOPENIA; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT RESPONSE; VOMITING;

EID: 78651071586     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318200e563     Document Type: Article

References (27)

1. Robinson LA, Ruckdeschel JC, Wagner H Jr, et al. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest 2007;132(Suppl 3):243S-265S.
2. Auperin A, Rolland E, Walter C, et al. Concomitant radio-chemotherapy (RT-CT) versus sequential RT-CT in locally advanced nonsmall cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomised clinical trials. J Thorac Oncol 2007;2:3009S.
3. Reguart N, Viñolas N, Casas F, et al. Integrating concurrent navelbine and cisplatin to hyperfractionated radiotherapy in locally advanced non-small cell lung cancer patients treated with induction and consolidation chemotherapy: feasibility and activity results. Lung cancer 2004; 45:67-75.
4. Graham MV, Pajak TE, Herskovic AM, et al. Phase I/II study of treatment of locally advanced (T3/T4) non-oat cell lung cancer with concomitant boost radiotherapy by the radiation therapy oncology group (RTOG 83-12): long-term results. J Radiot oncol Biol Phys 1995;31: 819-824.
5. Uitterhoeve ALJ, Belderbos JSA, Koolen MGJ, et al. Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II. Eur J Cancer 2000;36:592-600.
6. Casas F, Viñolas N, Ferrer F, et al. Improvement in performance status alters erythropoietin treatment in lung cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2003;55:116-124.
7. Therase P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92: 205-216.
8. World Health Organization. World Health Organization Hand Book for Reporting Results of Cancer Treatment. Publication no. 48. Geneva: World Health Organization, 1979.
9. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699.
10. Curran WJ, Scott C, Langer CJ, et al. Long-term benefits is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresectable stage III NSCLC:RTOG 9410 (Abstract 2499). Proc Am Soc Clin Oncol 2003;22:621.
11. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon Saint-Eteinne d'Oncologie Thoracique-Groupe Français de PneumoCancerologie NPC 95-01 Study. J Clin Oncol 2005;23:5910-5917.
12. Vokes EE, HernJE, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small cell lung cancer. Cancer and Leukemia Group B. J Clin Oncol 2007;25:1698-1704.
13. Kim MK, Kim SW, Choi EK, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone for unresectable stage III non-small cell lung cancer (NSCLC): randomized phase III trial. J Thorac Oncol 2007;2:3008S.
14. Huber RM, Fklentje M Scmidt M, et al. Simultaneous chemoradiation compared with radiotherapy alone after induction chemotherapy in inoperable stage IIA or IIIB non-small-cell lung cancer: Study CTRT 99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol 2006; 24:4397-4404.
15. Hanna N, NeubauerM, Ansari R, et al. Phase III trail of cisplatin (P), plus etoposide (E), plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients with inoperable stage III non-small cell lung cancer (NSCLC) HOG LUN01-24/USOP-023. J Clin Oncol 2008;26:5755-5760.
16. Senan S, De Ruysscher D, Giraud P, et al. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 2004;71:139-146.
17. Emani B, Perez CA, Herskovich, et al. Phase I/II of treatment of locally advanced (t3-T4) non-oat cell lung cancer with high dose radiotherapy (rapid fractionation). Int J Radiat Oncol Biol Phys 1988;15:1021-1025.
18. Sun L-M, Wan Leung S, Wang CJ, et al. Concomitant boost radiation therapy for inoperable non-small-cell lung cancer: preliminary report of a prospective randomized study. Int J Radiation Oncol Biol Phys 2000;47:413-418.
19. Saunders M, Dische S, Barret A, et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: a randomized multicentre trial. CHART Steering Committee. Lancet 1997;350:161-165.
20. Belani CP, Wang W, Jonson DH, et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and IIIB non-small-cell lung cancer. J Clin Oncol 2005;23: 3760-3767.
21. Liao Z, Komaki R, Stevens C, et al. Twice daily irradiation increases locoregional control in patients with medically inoperable or surgically unresectable stage II-IIIB non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;53:558-565.
22. Schaake-Koning C, van der Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-530.
23. Jeremic B, Shibamoto Y, Acimovic L, et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 1995;13: 452-458.
24. Casas F, Viñolas N. Toxicity of small cell lung cancer treatment. Hematol Oncol Clin N Am 2004;18:461-481.
25. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003; 21:2004-2010.
26. Glynne-Jones R, Hoskin P. Neoadjuvant cisplatin chemotherapy before chemoradiation: a flawed paradigm? J Clin Oncol 2007;25:5281-5286.
27. Godivan R, Bogart J, Vokes EE. Locally advanced non-small cell lung cancer: the past, present, and future. J Thorac Oncol 2008;3: 917-928.